Radiomedix,Inc. is a privately held biotechnology company founded in 2006 to develop and commercialize technology and products which will enable on-site and on-demand access to Positron Emission Tomography (“PET”). RadioMedix is developing its own chelation technology and new imaging conjugates, GlucoMedix and OncoMedix, which have the potential to significantly improve diagnosis and treatment monitoring for a variety of cancers.

RadioMedix’s automated SmartMedixTM system, coupled with a small generator producing a PET isotope such as Gallium-68 (68Ga), will permit users to generate and label PET radiotracers on-site. It will significantly reduce cost of radiosynthesis that can be performed without the need for costly cyclotron facilities.

RadioMedix is the exclusive distributor of all TRASIS and ITG radiopharmaceutical synthesizers in United States. RadioMedix also provides all the after sale service, installation and technical support for both TRASIS and ITG products in USA.